Table 3 Baseline data of macular degeneration patients reported in the FAERS database.
From: Real world pharmacovigilance assessment of drug related macular degeneration risks
Variables | Value | |
|---|---|---|
Age (year) | Mean + SD | 72.5 + 14.3 |
Median (Q1, Q3) | 66 (72, 82) | |
Weight (kg) | Mean + SD | 70.6 + 21.5 |
Median (Q1, Q3) | 69 (58, 82) | |
Gender | ||
Female | n (%) | 6822 (70.4%) |
Male | n (%) | 2238 (23.1%) |
Unknown | n (%) | 633 (6.5%) |
Outcome | ||
Other serious (important medical event) | n (%) | 8232 (80.1%) |
Hospitalization—initial or prolonged | n (%) | 1333 (13.0%) |
Disability | n (%) | 513 (5.0%) |
Death | n (%) | 118 (1.1%) |
Life threatening condition | n (%) | 55 (0.5%) |
Required intervention to prevent | n (%) | 26 (0.3%) |
Country | ||
United States | n (%) | 6471 (66.8%) |
Canada | n (%) | 1200 (12.4%) |
Others | n (%) | 1055 (10.9%) |
Germany | n (%) | 306 (3.2%) |
United Kingdom | n (%) | 172 (1.8%) |
Japan | n (%) | 128 (1.3%) |
Australia | n (%) | 111 (1.1%) |
Brazil | n (%) | 90 (0.9%) |
Switzerland | n (%) | 88 (0.9%) |
France | n (%) | 72 (0.7%) |
